ReviewJournal of neurology2016
Immune-mediated processes in neurodegeneration: where do we stand?
Review in Journal of neurology, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 24 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
24 citing papers in PubMed.
- Conserved Pathways, Divergent Outcomes: A Cross-Species Genomic Perspective on the Cancer-Neurodegeneration Paradox.International journal of molecular sciences · 2026Review
- The Therapeutic Potential of Butyrate and Lauric Acid in Modulating Glial and Neuronal Activity in Alzheimer's Disease.Nutrients · 2025Review
- Mitochondria and Brain Disease: A Comprehensive Review of Pathological Mechanisms and Therapeutic Opportunities.Biomedicines · 2023Review
- The role of microRNAs in neurodegenerative diseases: a review.Cell biology and toxicology · 2023Review
- Gcm counteracts Toll-induced inflammation and impacts hemocyte number through cholinergic signaling.Frontiers in immunology · 2023Article
- Systemic inflammatory markers in patients with polyneuropathies.Frontiers in immunology · 2023Article
- Reduced Prevalence of Dementia in Patients Prescribed Tacrolimus, Sirolimus, or Cyclosporine.Journal of Alzheimer's disease : JAD · 2023Article
- Therapeutic Potential of Microbiota Modulation in Alzheimer's Disease: A Review of Preclinical Studies.Journal of Alzheimer's disease reports · 2023Review
- Novel patients with NHLRC2 variants expand the phenotypic spectrum of FINCA disease.Frontiers in neuroscience · 2023Article
- Inflammation-Mediated Responses in the Development of Neurodegenerative Diseases.Advances in experimental medicine and biology · 2023Review
- Key brain cell interactions and contributions to the pathogenesis of Alzheimer's disease.Frontiers in cell and developmental biology · 2022Review
- The Innate and Adaptive Immune Cells in Alzheimer's and Parkinson's Diseases.Oxidative medicine and cellular longevity · 2022Review
- Microglia in Alzheimer's Disease: The Role of Stem Cell-Microglia Interaction in Brain Homeostasis.Neurochemical research · 2021Review
- The Selective Loss of Purkinje Cells Induces Specific Peripheral Immune Alterations.Frontiers in cellular neuroscience · 2021Article
- Anti-Inflammatory Properties of Statin-Loaded Biodegradable Lecithin/Chitosan Nanoparticles: A Step Toward Nose-to-Brain Treatment of Neurodegenerative Diseases.Frontiers in pharmacology · 2021Article
- The Air We Breathe: Air Pollution as a Prevalent Proinflammatory Stimulus Contributing to Neurodegeneration.Frontiers in cellular neuroscience · 2021Article
- From the low-density lipoprotein receptor-related protein 1 to neuropathic pain: a potentially novel target.Pain reports · 2021Review
- Epigenetic Modulation of Microglia Function and Phenotypes in Neurodegenerative Diseases.Neural plasticity · 2021Review
- Kynurenine pathway metabolites selectively associate with impaired associative memory function in depression.Brain, behavior, & immunity - health · 2020Article
- HLA and microtubule-associated protein tau H1 haplotype associations in anti-IgLON5 disease.Neurology(R) neuroimmunology & neuroinflammation · 2019Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Neurodegeneration is a pathological condition that predominantly affects neurons. It represents a large spectrum of disorders with heterogeneous symptoms and distinct clinical features. In addition to the devastating effects it can have on the affected individual, it constitutes a heavy burden to the society in terms of health care costs. Although the exact cause of neurodegeneration is not known, there are plenty of evidences supporting the notion that the immune system is strongly associated with various forms of neurodegenerative diseases. Given the numerous functions of immune cells, a change in their expression can either be beneficial or deleterious to the host. A better understanding of the molecular and cellular processes in neurodegeneration is therefore needed. This could facilitate the development of new therapeutic targets and provide effective means to dampen the progression of neurodegenerative disorders. The overarching aim of this paper is to provide an overview of the roles that the innate and adaptive immune systems play in the central nervous system, and to discuss their beneficial or detrimental effects during neurodegeneration. This paper also critically examines the contribution of immune and inflammatory-mediated responses in the development of neurodegenerative diseases including Alzheimer's disease (AD), Parkinson's disease (PD), multiple sclerosis (MS), and amyloid lateral sclerosis by illustrating key findings from animal and human studies.
Indexed as
Identifiers
26872669What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.